Peritonitis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Peritonitis – Pipeline Review, H1 2018’, provides an overview of the Peritonitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritonitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Peritonitis

– The report reviews pipeline therapeutics for Peritonitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Peritonitis therapeutics and enlists all their major and minor projects

– The report assesses Peritonitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Peritonitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Peritonitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peritonitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenium Biotech ApS

GlaxoSmithKline Plc

Oncodesign SA

SynAct Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Peritonitis Overview 6

Peritonitis Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Peritonitis Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Peritonitis Companies Involved in Therapeutics Development 21

Adenium Biotech ApS 21

GlaxoSmithKline Plc 21

Oncodesign SA 21

SynAct Pharma AB 22

Peritonitis Drug Profiles 23

AA-139 Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

AcPepA Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

AP-1189 Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

molgramostim Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

R-10001 Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit Nitric Oxide Synthase for Rheumatism, Arthritis and Peritonitis Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

SRT-3025 Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Peritonitis Dormant Projects 34

Peritonitis Product Development Milestones 35

Featured News & Press Releases 35

Jun 19, 2016: Reponex Pharmaceuticals: The Danish Medicines Agency has approved the clinical trial protocol for the peritonitis project 35

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development for Peritonitis, H1 2018 7

Number of Products under Development by Companies, H1 2018 9

Number of Products under Development by Universities/Institutes, H1 2018 10

Products under Development by Companies, H1 2018 11

Products under Development by Universities/Institutes, H1 2018 12

Number of Products by Stage and Target, H1 2018 14

Number of Products by Stage and Mechanism of Action, H1 2018 16

Number of Products by Stage and Route of Administration, H1 2018 18

Number of Products by Stage and Molecule Type, H1 2018 20

Peritonitis Pipeline by Adenium Biotech ApS, H1 2018 21

Peritonitis Pipeline by GlaxoSmithKline Plc, H1 2018 21

Peritonitis Pipeline by Oncodesign SA, H1 2018 22

Peritonitis Pipeline by SynAct Pharma AB, H1 2018 22

Peritonitis Dormant Projects, H1 2018 34

List of Figures

List of Figures

Number of Products under Development for Peritonitis, H1 2018 7

Number of Products under Development by Companies, H1 2018 8

Number of Products by Targets, H1 2018 13

Number of Products by Stage and Targets, H1 2018 13

Number of Products by Mechanism of Actions, H1 2018 15

Number of Products by Stage and Mechanism of Actions, H1 2018 15

Number of Products by Routes of Administration, H1 2018 17

Number of Products by Stage and Routes of Administration, H1 2018 17

Number of Products by Molecule Types, H1 2018 19

Number of Products by Stage and Molecule Types, H1 2018 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports